Cero Therapeutics Holdings Stock Alpha and Beta Analysis
| CEROW Stock | 0.01 0 17.57% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as CERo Therapeutics Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in CERo Therapeutics over a specified time horizon. Remember, high CERo Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to CERo Therapeutics' market risk premium analysis include:
Beta (1.95) | Alpha 3.45 | Risk 38.59 | Sharpe Ratio 0.11 | Expected Return 4.3 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. CERo Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. CERo Therapeutics market risk premium is the additional return an investor will receive from holding CERo Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in CERo Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate CERo Therapeutics' performance over market.| α | 3.45 | β | -1.95 |
CERo Therapeutics Fundamentals Vs Peers
Comparing CERo Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze CERo Therapeutics' direct or indirect competition across all of the common fundamentals between CERo Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as CERo Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of CERo Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing CERo Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare CERo Therapeutics to competition |
| Fundamentals | CERo Therapeutics | Peer Average |
| Return On Asset | -2.1 | -0.14 |
| Number Of Shares Shorted | 12.1 K | 4.71 M |
| Gross Profit | (500 K) | 27.38 B |
| EBITDA | (6.57 M) | 3.9 B |
| Net Income | (8.3 M) | 570.98 M |
| Total Debt | 1.58 M | 5.32 B |
| Book Value Per Share | (8.85) X | 1.93 K |
CERo Therapeutics Opportunities
CERo Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Cero Therapeutics amends purchase agreement, completes initial closing for 2.25 million - Investing.com | 10/16/2025 |
2 | Why CERo Therapeutics Holdings Inc. stock is rated strong buy - Trade Signal Summary Entry Point Strategy Guides - newser.com | 10/30/2025 |
3 | Acquisition by Byrnes Michael of 9326 shares of CERo Therapeutics at 0.4454 subject to Rule 16b-3 | 10/31/2025 |
4 | CERo Therapeutics Announces Listing on OTC Markets - GlobeNewswire | 11/03/2025 |
5 | Why CERo Therapeutics Holdings Inc. Equity Warrant stock remains resilient - July 2025 Momentum AI Powered BuySell Recommendations - fcp.pa.gov.br | 11/06/2025 |
6 | Using flow based indicators on CERo Therapeutics Holdings Inc. - Market Performance Recap Real-Time Stock Price Movement Reports - newser.com | 11/10/2025 |
7 | Using fundamentals and technicals on CERo Therapeutics Holdings Inc. Equity Warrant - 2025 Geopolitical Influence High Accuracy Investment Signals - newser.com | 11/13/2025 |
8 | Will CERo Therapeutics Holdings Inc. stock recover faster than market - July 2025 PostEarnings Weekly Hot Stock Watchlists - newser.com | 11/19/2025 |
About CERo Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including CERo or other stocks. Alpha measures the amount that position in CERo Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 0.38 | 0.5 | 0.58 | 0.55 | Net Debt To EBITDA | 0.019 | 0.27 | 0.31 | 0.29 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CERo Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CERo Therapeutics' short interest history, or implied volatility extrapolated from CERo Therapeutics options trading.
Build Portfolio with CERo Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.